SCHEMBL80842

SCHEMBL80842

O=[C]C1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27646052 1.00
SCHEMBL475384 1.00
SCHEMBL348692 0.92
SCHEMBL4955059 0.92
SCHEMBL9549203 0.90 CYP2D6 (0.38)
SCHEMBL518834 0.90 CYP2D6 (0.38)
SCHEMBL82934 0.90
SCHEMBL518712 0.85 SMN1; SMN2 (0.35)
SCHEMBL519521 0.85
SCHEMBL676844 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3921319-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP claimed
US-20230398529-A1 ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST BAYER AKTIENGESELLSCHAFT (DE) 2023-12-14 US claimed
EP-4229040-A1 ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST Bayer Aktiengesellschaft (DE) 2023-08-23 EP claimed
US-11702431-B2 Oxo-substituted compound Sumitomo Pharma Co., Ltd. (JP) 2023-07-18 US claimed
CN-116348452-A Asymmetric transfer hydrogenation of 2-aryl substituted bicyclic pyridones in the presence of chiral ruthenium catalysts 拜耳公司 2023-06-27 CN claimed
US-20230167117-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEONE MEDICINES I GMBH (CH) 2023-06-01 US claimed
US-20230167109-A1 Aminopiperidine Amides, Derivatives, Compositions, and Uses Related to CXCR4 Modulation UNIV EMORY (US) 2023-06-01 US claimed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US claimed
US-11596716-B2 Compounds and matrices for use in bone growth and repair HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2023-03-07 US claimed
US-20230038124-A1 NOVEL SUBSTITUTED CONDENSED RING COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2023-02-09 US claimed
WO-1997006178-A1 PYRIMIDINE NUCLEOSIDES F. HOFFMANN-LA ROCHE AG (CH) 1997-02-20 WO claimed
WO-1995032217-A1 PEPTIDE ANTAGONIST INTERMEDIATES OF NEUROTENSIN RHONE-POULENC RORER S.A. (FR) 1995-11-30 WO claimed
WO-1995032218-A1 NEUROTENSIN ANTAGONIST PEPTIDES RHONE-POULENC RORER S.A. (FR) 1995-11-30 WO claimed
EP-0618222-A2 Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid CIBA-GEIGY AG (CH) 1994-10-05 EP claimed
WO-1993000359-A1 MODIFIED PEPTIDES TRANSPORTABLE INTO THE CENTRAL NERVOUS SYSTEM THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-01-07 WO claimed
EP-0169812-B1 PHOSPHATIDYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1989-08-23 EP claimed
EP-0099057-B1 N-ACYL DERIVATIVES OF PEPTIDES, THEIR MANUFACTURE AND USE IN COMBATING DISEASES AND MEANS THEREFOR BASF Aktiengesellschaft (DE) 1987-10-14 EP claimed
US-4610817-A N-acyl derivatives of peptides, their preparation and their use in the treatment of disorders, and agents for this purpose BASF AKTIENGESELLSCHAFT (DE) 1986-09-09 US claimed
EP-0169812-A1 Phosphatidyl compounds, process for their preparation and their use CIBA-GEIGY AG (CH) 1986-01-29 EP claimed
EP-0099057-A2 N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor BASF Aktiengesellschaft (DE) 1984-01-25 EP claimed